Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of ABX464 50 mg once daily in moderate to severe ulcerative colitis
2017-003284-35Phase 2Completed
- Sponsor
- Abivax
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obefazimod in autoimmune colitis, sponsored by Abivax. Primary endpoint: Treatment-emergent adverse events. Started Nov 2017; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-003284-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003284-35.